Indivior PLC (OTC: INVVY)
Hagens Berman Sobol Shapiro LLP alerts investors in Indivior PLC (OTC: INVVY) to the firm’s investigation of possible Federal securities law violations.
If you purchased or otherwise acquired securities of INVVY before March 10, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more infomation contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing INVVY@hbsslaw.com.
On March 10, 2019, the financial press reported that (a) “a federal grand jury in Virginia indicted the drugmaker for allegedly ‘engaging in an illicit nationwide scheme’ to push prescriptions of a drug used in the treatment of opioid addiction,” and (b) [t]he U.S. is seeking ‘not less than’ $3 billion in fines over the allegations.”
This news drove the price of Indivior securities sharply lower during intraday trading on March 10, 2019.
“We’re focused on investors’ losses, whether the Company and senior management deceived health care providers and health care benefit programs about the safety of Suboxone Film and, if so, the extent to which investors may have also been misled,” said Hagens Berman partner Reed Kathrein.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.